New Weight Loss Drugs Reshape Stock Market as Millions Shed Pounds

GLP-1 weight loss drugs like Ozempic are poised to reshape sectors across the stock market as millions lose weight.

Drug makers Novo Nordisk and Eli Lilly have surged to become Europe's largest company and a top 10 S&P 500 company.

The drugs' obesity and diabetes benefits have slammed medical device companies like CPAP and insulin pump manufacturers.

Food retailers are already seeing lower purchases as the drugs make people eat less.

Widespread adoption could boost productivity and deliver healthcare cost savings, while reducing demand for certain treatments.